These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17402790)

  • 1. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
    Bedard PL; de Azambuja E; Cardoso F
    Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
    Flaherty KT; Brose MS
    Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
    Abramovitz M; Williams C; Loibl S; Leyland-Jones B
    Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatment approaches in breast cancer].
    Spirig C; Thürlimann B; Huober J
    Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
    Widakowich C; Dinh P; de Azambuja E; Awada A; Piccart-Gebhart M
    Anticancer Agents Med Chem; 2008 Jun; 8(5):488-96. PubMed ID: 18537532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies and breast cancer. Current therapeutic progress].
    Collignon J; Gennigens C; Rorive A; Coucke P; Lifrange E; Maweja S; Fillet G; Jerusalem G
    Rev Med Liege; 2009; 64(5-6):279-83. PubMed ID: 19642459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tykerb for breast cancer].
    Suzuki Y; Saito Y; Okamura T; Tokuda Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and HER-2 antagonists in breast cancer.
    O'Donovan N; Crown J
    Anticancer Res; 2007; 27(3A):1285-94. PubMed ID: 17593621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
    Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.